# EDGAR Filing Document

**Accession Number:** 0001829247
**File Stem:** 0001641172-25-014872
**Filing Date:** 2025-6
**Character Count:** 9630
**Document Hash:** 9cd2dec43e2fa51aca1cf0868aca877b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-014872.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001641172-25-014872

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BullFrog AI Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001829247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844786155
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41600
- **FILM NUMBER:** 251043371

**BUSINESS ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878
- **BUSINESS PHONE:** 3013672055

**MAIL ADDRESS:**
- **STREET 1:** 325 ELLINGTON BLVD.
- **STREET 2:** UNIT 317
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 12, 2025

**BULLFROG AI HOLDINGS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41600** | **84-4786155** |
| (State or other jurisdiction of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**325 Ellington Blvd, Unit 317**

**Gaithersburg, MD 20878**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(240) 658-6710**

**Not Applicable**

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.00001<br> per share | BFRG | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |
| Tradeable Warrants | BFRGW | The Nasdaq Stock Market LLC<br> (The Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On June 12, 2025, BullFrog AI Holdings, Inc. issued a press release announcing its entry into a collaboration agreement with Sygnature Discovery Limited. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| (d) | Exhibits.<br>|
|  | The following exhibit is being furnished herein: |
| 99.1 | [Press release, dated June 12, 2025](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 12, 2025 | **BullFrog AI Holdings, Inc.** | **BullFrog AI Holdings, Inc.** |
|  | By: | */s/ Vininder Singh* |
|  | Name: | Vininder Singh |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients**

The collaboration marks a significant commercial milestone for BullFrog AI and is expected to greatly accelerate brand recognition and user uptake to generate between **$15-$30** million in revenue for BullFrog AI through 2028.

"This collaboration agreement with Sygnature Discovery is a major step forward in our mission to democratize access to cutting-edge AI tools that accelerate drug discovery," said Vin Singh, Founder and CEO of BullFrog AI. "By highlighting BullFrog Data Networks as part of Sygnature's comprehensive suite of discovery solutions, we build brand recognition within a high-quality global client base that is actively engaged in early-stage target discovery—an area where our platform adds tremendous value."

BullFrog Data Networks™ accelerates the exploration of complex, high-dimensional, multi-modal datasets, uncovering hidden relationships and novel pathways critical to understanding disease biology. This powerful platform supports vital research applications including early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization. Delivered through an intuitive, visual, and disease-centric interface, BullFrog Data Networks empowers researchers to confidently make informed, strategic decisions faster than ever before.

"Sygnature Discovery is committed to offering a range of best-in-class tools to our clients across the drug discovery continuum," said Stuart Onions, Chief Technical Officer at Sygnature Discovery. "BullFrog AI's platform further complements our capabilities in target discovery and data interpretation, helping relevant clients who express an interest in the technology to unlock the full potential of their datasets and improve R&D efficiency and success rates."

BullFrog AI's scalable Data Networks offering was designed to meet the needs of small to mid-sized biopharma companies, a segment often underserved by existing bioinformatics solutions. Through this collaboration, BullFrog and Sygnature Discovery can accelerate innovation across a wide range of therapeutic areas.

**About BullFrog AI**

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at: <u>https://bullfrogai.com</u>

**Safe Harbor Statement**

This press release contains forward-looking statements, including the revenues to be generated in connection with this collaboration. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners' ability to market and sell our offerings and servicings, including BullFrog Data Networks™ and the competitive environment of our business. In particular, there can be no assurance as to the actual revenues to be received from this collaboration, which are subject to a number of factors and risks, such as Sygnature's ability to effectively sell BullFrog Data Networks™ to its clients. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.

1-407-644-4256

<u>BFRG@redchip.com</u>